Treatment with DQ did not affect tumor burden or P1NP levels; however, it restored p16Ink4a expression to control levels and decreased by ~50% CTX levels in bones bearing breast cancer cells (Fig. 7f–g). Here, CDKN2A is linked to breast cancer.